High Graphics
|
Low Graphics
Tuesday 6 January, 2009
Home
About Us
FeedBack
Contact Us
Latest Headlines
|
Word Search
Comment
Genmab will have to wait for partner
News that the phase III trial of Genmab’s zalutumumab in head and neck cancer did not meet a high enough efficacy hurdle to warrant discontinuing the study and giving all patients the drug is not a hu...
6 Jan 2009
UCB's Cimzia RA delay prompts well founded jitters
While UCB’s Cimzia is being held up as one of 2008’s more significant drug approvals in the US, following a green light for Crohn’s disease in April, the FDA’s hesitance with regards to the far more i...
6 Jan 2009
Notable deals over the Christmas period
EP Vantage brings you notable deals you may have missed over the Christmas period....
5 Jan 2009
Notable regulatory events over the Christmas period
EP Vantage brings you notable regulatory events that you may have missed over the Christmas break.December 24Takeda’s new anti-diabetic agent, alogliptin, a DDP-IV inhibitor in the same class as Merck...
5 Jan 2009
1
2
What is this?
View Archive
Showing headlines from the
Past 7 Days
Retrieving...
Analysis
Endo hits the acquisition trail
The new year may have only been five days old, but Endo Pharmaceuticals became the first company out of the mergers and acquisitions blocks, when it announced yesterday that it would be paying $370m i...
6 Jan 2009
What is this?
View Archive
Showing headlines from the
Past 7 Days
Retrieving...
EventAnalyzer
EventAnalyzer: Daily Market Movers (5 Jan 2009)
6 Jan 2009
EventAnalyzer: Weekly Market Movers (to 2 Jan 2009)
5 Jan 2009
What is this?
View Archive
Showing
the Most Recent Headlines
Retrieving...
Home
|
About Us
|
Feedback
|
Contact Us
|
Terms & Conditions
Register for a free trial
Related Links
Registered Users
Word Search
Enter your free-text query in the box below
Searching...